Given a mean corpuscular hemoglobin concentration (MCHC) of 31.3 g/dL, platelet count of 425 ×10⁹/L (thrombocytosis), mean platelet volume (MPV) of 9.0 fL, fasting glucose of 104 mg/dL (borderline‑high), serum sodium of 136 mmol/L, estimated glomerular filtration rate (eGFR) of 66.6 mL/min/1.73 m² (mildly reduced renal function), iron 118 µg/dL, uric acid 5.2 mg/dL, total cholesterol 270 mg/dL (hypercholesterolemia), LDL cholesterol 151 mg/dL (elevated LDL), vitamin B12 443 pg/mL, and vitamin D 21.7 ng/mL (vitamin D deficiency), what is the likely diagnosis and how should I treat these findings?

Multiple Metabolic Abnormalities Requiring Targeted Interventions

You have several distinct metabolic abnormalities that require specific treatment: vitamin D deficiency (21.7 ng/mL), hypercholesterolemia with elevated LDL (270 mg/dL total cholesterol, 151 mg/dL LDL), mildly reduced kidney function (eGFR 66.6 mL/min/1.73 m²), borderline glucose intolerance (104 mg/dL), and mild thrombocytosis (425 ×10⁹/L).

Primary Concerns and Treatment Priorities

1. Hypercholesterolemia and Cardiovascular Risk (Most Critical)

Your total cholesterol of 270 mg/dL and LDL of 151 mg/dL place you at increased cardiovascular risk, particularly given your mildly reduced kidney function (eGFR 66.6). You need statin therapy initiated immediately 1, 2.

Treatment approach:

• Start a moderate-intensity statin (e.g., atorvastatin 10-20 mg or rosuvastatin 5-10 mg daily) 1, 2
• Target LDL-C <100 mg/dL as primary goal; ideally <70 mg/dL given your kidney dysfunction 3, 1
• With eGFR 60-89 mL/min/1.73 m², you can safely use statins but require monitoring 4, 5
• If LDL remains >100 mg/dL after 4-6 weeks on maximally tolerated statin, add ezetimibe 10 mg daily 6, 1

Critical caveat: Your reduced eGFR (66.6) places you at "very high to extremely high risk for ASCVD events" 1. Patients with CKD stages 3a-3b (eGFR 45-59) should be treated aggressively with statins, and higher doses have proven safe in this setting 4, 5.

2. Vitamin D Deficiency (Requires Immediate Correction)

Your vitamin D level of 21.7 ng/mL represents insufficiency (optimal ≥30 ng/mL).

Treatment:

• Vitamin D3 (cholecalciferol) 2,000-4,000 IU daily for 8-12 weeks
• Recheck 25(OH)D level after 3 months
• Maintenance dose of 1,000-2,000 IU daily once replete

Important consideration: Vitamin D deficiency may be contributing to your mild thrombocytosis. Recent evidence shows vitamin D treatment can lower platelet counts 7, 8. While your platelet count of 425 ×10⁹/L is only mildly elevated and likely reactive (secondary), correcting vitamin D deficiency may help normalize this 7, 9.

3. Mildly Reduced Kidney Function (eGFR 66.6)

Your eGFR of 66.6 mL/min/1.73 m² indicates CKD stage 2 (mild reduction). This is significant because:

• CKD independently increases cardiovascular risk 2-4 fold 4
• You require more aggressive lipid management than someone with normal kidney function 4, 5
• Blood pressure control becomes critical (target <130/80 mmHg if you have hypertension) 10

Monitoring requirements:

• Recheck eGFR and urine albumin-to-creatinine ratio (ACR) annually 5, 10
• If ACR >30 mg/g develops, start ACE inhibitor or ARB regardless of blood pressure 10
• Monitor for progression; if eGFR drops below 60, you enter CKD stage 3a with higher risk 4

4. Borderline Glucose (104 mg/dL)

Your fasting glucose of 104 mg/dL indicates impaired fasting glucose (prediabetes: 100-125 mg/dL).

Management:

• Lifestyle modification is first-line: weight loss if overweight (target 5-7% body weight reduction), 150 minutes/week moderate aerobic exercise, low-glycemic diet 6, 10
• Check HbA1c to better assess glycemic status
• Recheck fasting glucose in 3-6 months
• If HbA1c ≥5.7% or fasting glucose remains elevated, consider metformin 500-850 mg daily (if eGFR >45) 10

5. Mild Thrombocytosis (425 ×10⁹/L)

Your platelet count of 425 ×10⁹/L is mildly elevated (thrombocytosis defined as >450 ×10⁹/L by most guidelines, though some use >400) 11.

This is almost certainly reactive (secondary) thrombocytosis given:

• Only mild elevation
• Normal MPV (9.0 fL)
• Presence of vitamin D deficiency (which can elevate platelets) 7, 8
• No other concerning blood count abnormalities mentioned

Approach:

• No specific treatment needed for mild reactive thrombocytosis 11, 12, 13
• Repeat CBC in 3 months after vitamin D correction
• If platelets remain >450 ×10⁹/L persistently, check CRP and ferritin to identify inflammatory or iron deficiency causes 11, 12
• Do NOT pursue JAK2/CALR/MPL testing unless platelets >450 persistently without identifiable cause 11, 12
• No aspirin indicated for reactive thrombocytosis alone 14

6. Other Laboratory Values

• MCHC 31.3 g/dL: Low-normal, no action needed
• Sodium 136 mmol/L: Low-normal, no action needed unless symptomatic
• Iron 118 µg/dL: Normal
• Uric acid 5.2 mg/dL: Normal
• Vitamin B12 443 pg/mL: Normal

Comprehensive Treatment Plan

Immediate actions (start now):

1. Statin therapy: atorvastatin 10-20 mg or rosuvastatin 5-10 mg daily
2. Vitamin D3: 2,000-4,000 IU daily
3. Lifestyle modifications: diet (reduce saturated fat, increase fiber), exercise 150 min/week, weight loss if overweight

Follow-up testing in 4-6 weeks:

• Lipid panel (assess statin response)
• Liver enzymes (monitor statin safety)
• Creatine kinase if muscle symptoms develop

Follow-up testing in 3 months:

• 25(OH)D level (assess vitamin D repletion)
• CBC (reassess platelet count after vitamin D correction)
• HbA1c (better assess diabetes risk)
• Fasting glucose
• eGFR and urine ACR (monitor kidney function)

Medication adjustments at 3 months:

• If LDL >100 mg/dL: add ezetimibe 10 mg daily 6, 1
• If vitamin D <30 ng/mL: continue higher-dose supplementation
• If platelets remain >450 ×10⁹/L: check CRP, ferritin 11, 12

Critical Pitfalls to Avoid

1. Do not delay statin therapy - your combination of elevated LDL and reduced eGFR places you at very high cardiovascular risk 1, 4
2. Do not over-investigate the mild thrombocytosis - avoid expensive molecular testing (JAK2, etc.) unless platelets persistently >450 after treating vitamin D deficiency 11, 12
3. Do not ignore the kidney dysfunction - eGFR 66.6 requires annual monitoring and aggressive cardiovascular risk factor management 4, 5
4. Do not use fibrates or high-dose niacin as first-line - statins are superior for cardiovascular outcomes 3, 15, 1
5. Monitor for statin-related muscle symptoms but do not stop without trying alternative statins or lower doses 1